| Capecitabine | advanced breast cancer (metastatic), in all type of patients | vs CMF | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Oshaughnessy, 2001 | intermittent oral capecitabine 1,255 mg/m2 twice daily (two weeks treatment followed by a one-week rest period) | intravenous CMF (cyclophosphamide. methotrexate, 5-fluorouracil [5-FU]) administered every three weeks | -line therapy for advanced/metastatic breast cancer |
| |
| Capecitabine | | vs cyclophosphamide, methotrexate, and 5-fluorouracil | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Stockler, 2011 | | | |
| |
| Capecitabine | | vs IV CT | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Hori, 0 | capecitabine, + medroxyprogesterone acetate (MPA) + cyclophosphamide | 5-fluorouracil + adriamycin + CPA) plus MPA | metastatic breast cancer |
| |
| Capecitabine | | vs pegylated liposomal doxorubicin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Jäger, 2010 | | | |
| |
| Capecitabine | | vs vinorelbine | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| EORTC 10001 (Pajk), 2008 | capecitabine 1250 mg/m(2) orally bid days 1-14 | vinorelbine 30 mg/m(2) i.v. days 1 and 8, both given every 3 weeks | patients with anthracycline- and taxane-pretreated metastatic breast cancer |
| |
| Capecitabine | | vs control | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Joensuu, 2009 | three cycles of capecitabine and docetaxel followed by three cycles of cyclophosphamide, epirubicin, and capecitabine | three cycles of docetaxel followed by three cycles of cyclophosphamide, epirubicin, and fluorouracil | women with axillary node-positive or high-risk node-negative breast cancer |
| |
| Capecitabine | | vs docetaxel | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| GeparQuattro, 2010 | | | Patients with large operable or locally advanced tumors, with hormone receptor-negative tumors, or with receptor-positive tumors but also clinically node-positive disease |
| |
| Capecitabine | | vs docetaxel + epirubicin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Mavroudis, 2010 | docetaxel 75 mg/m(2) on day 1 plus capecitabine 950 mg/m(2) orally twice daily on days 1-14 (DC) in 21-day cycles | docetaxel 75 mg/m(2) plus epirubicin 75 mg/m(2) (DE) on day 1 | women with advanced breast cancer |
| |
| Capecitabine | | vs docetaxel alone | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Verma, 2005 | 21-day cycles of oral capecitabine 1250 mg/m2 twice daily, on Days 1-14, plus docetaxel 75 mg/m2 Day 1 | docetaxel 100 mg/m2 on Day 1 | patients with anthracycline-pretreated metastatic breast carcinoma | | Miles, 2004 | | | patients with anthracycline-pretreated advanced/metastatic breast cancer | | OShaughnessy, 2002 | 21-day cycles of oral capecitabine 1,250 mg/m(2) twice daily on days 1 to 14 plus docetaxel 75 mg/m(2) on day 1 | docetaxel 100 mg/m(2) on day 1 | patients with advanced breast cancer |
| |
| Capecitabine | | vs doxorubicin + cyclophosphamide | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Lee, 2008 | | | women with axillary node positive, stage II/III breast cancer |
| |
| Capecitabine | | vs paclitaxel | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Talbot, 2002 | intermittent oral capecitabine (1255 mg m(-2) twice daily, days 1-14, (22 patients)) | i.v. paclitaxel (175 mg m(-2), | patients with metastatic/advanced breast cancer pretreated with anthracyclines | | Moiseenko, 2000 | | | |
| |
